A Phase 3 interventional study of Dulaglutide and Insulin glargine in Type 2 Diabetes Mellitus, sponsored by Eli Lilly and Company. Completed at 30 sites in 4 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-09-18.
Sponsored by Eli Lilly and Company · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 54 studies testing dulaglutide in Diabetes Mellitus, Type 2 — 3 open to participants now, 4 under way, 1 of them phase 3. dulaglutide · Diabetes Mellitus, Type 2.
Among the 54 studies testing dulaglutide in Diabetes Mellitus, Type 2, this one is the 8th largest by enrollment, is one of 8 that started in 2012, is one of 22 in phase 3, and was the 25th registered.
10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.
Browse Diabetes Mellitus, Type 2 studies →3 of the 54 studies testing dulaglutide in Diabetes Mellitus, Type 2 are open now, in 3 countries. Recruiting first, the newest first:
Eli Lilly and Company · Sites in United States, Argentina, Mexico
Ages 10–17
First Affiliated Hospital of Wannan Medical College
Ages 18+
Seoul National University Bundang Hospital
Ages 20–90
By country, each count listing its studies:
dulaglutide: first FDA approval 2014 (TRULICITY), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →
Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
54 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 15 · Phase 2 6 · Phase 3 23 · Phase 4 9
First in 2008; this study’s year is marked. 8 started in 2012.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 774 is above the median of 80 across 8,361 interventional studies indexed under Diabetes Mellitus, Type 2.
Median enrollment 159 across the 54 interventional studies. Of the 47 that completed or were terminated, 38 (81%) have results posted.
This tab as a report to print or save as PDF → With an account.
45 of 54 have an industry lead sponsor. The 10 most frequent:
Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.
Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.
238 studies in Diabetes Mellitus, Type 2 by Eli Lilly and Company: 10 open now, 21 under way, 11 of them phase 3. Of 211 finished, 155 (73%) have results posted.
Among the 238 studies in Diabetes Mellitus, Type 2 by Eli Lilly and Company, this one is the 38th largest by enrollment of the 232 interventional ones that give a count, is one of 14 that started in 2012, is one of 85 in phase 3, and was the 88th registered.
Eli Lilly and Company’s Diabetes Mellitus, Type 2 studies by the year they started, since 2001.
1 of the studies testing dulaglutide in Diabetes Mellitus, Type 2 that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07537088First Affiliated Hospital of Wannan Medical CollegeEfficacy and Safety of Triple Therapy With Dulaglutide, SGLT2 Inhibitors, and Finerenone in Chinese Adults With Type 2 Diabetes and Chronic Kidney Disease | 2027-04 |
Add it to your calendar (.ics) → With an account.
Among the 54 studies testing dulaglutide in Diabetes Mellitus, Type 2, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Eli Lilly and Company’s 238 in Diabetes Mellitus, Type 2:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to examine if once-weekly dulaglutide is efficient and safe compared to once-daily insulin glargine in participants with type 2 diabetes mellitus who have inadequate glycemic control with 1 or 2 oral antihyperglycemic medications (OAM) (metformin and/or a sulfonylurea), in addition to any healthy lifestyle changes recommended by their healthcare providers.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
1.5 milligrams (mg) dulaglutide administered as one subcutaneous (SC) injection once-weekly added to participant's pre-study prescribed dose of metformin and/or a sulfonylurea for up to 52 weeks. Participants are blinded to the dulaglutide dose.
Drug: Dulaglutide · Drug: Metformin · Drug: Sulfonylureas
0.75 mg Dulaglutide administered as one SC injection once-weekly added to participant's pre-study prescribed dose of metformin and/or a sulfonylurea for up to 52 weeks. Participants are blinded to the dulaglutide dose.
Drug: Dulaglutide · Drug: Metformin · Drug: Sulfonylureas
Insulin glargine administered based on fasting blood glucose concentrations per the dosing titration schedule as once daily SC injection at bedtime added to participant's pre-study prescribed dose of metformin and /or a sulfonylurea for up to 52 weeks.
Drug: Insulin glargine · Drug: Metformin · Drug: Sulfonylureas
Administered SC
Also known as: LY2189265
Administered SC per dosing titration schedule
Administered orally at pre-study prescribed dose, and is not being provided as part of the trial.
Administered orally at pre-study prescribed dose, and is not being provided as part of the trial.
Change From Baseline in Glycosylated Hemoglobin (HbA1c) at 26 Weeks
HbA1c is a form of hemoglobin that is measured primarily to identify the average plasma glucose concentration over prolonged periods of time. Least square (LS) means of change from baseline in HbA1c were calculated using a mixed-effects model for repeated measures (MMRM) with the change in HbA1c as the dependent variable and treatment, baseline HbA1c, country, oral antihyperglycemic medication (OAM) , visit, and treatment-by-visit interaction as fixed effects, and participant was the random effect.
Time frame: Baseline, 26 Weeks
Change From Baseline in HbA1c at 52 Weeks
HbA1c is a form of hemoglobin that is measured primarily to identify the average plasma glucose concentration over prolonged periods of time. LS means of change from baseline in HbA1c were calculated using a MMRM with the change in HbA1c as the dependent variable and treatment, baseline HbA1c, country, OAM, visit, and treatment-by-visit interaction as fixed effects, and participant was as the random effect.
Time frame: Baseline, 52 Weeks
Percentage of Participants Attaining HbA1c of <7% or ≤6.5% at 26 Weeks and 52 Weeks
The percentage of participants was calculated by dividing the number of participants reaching target HbA1c by the total number of participants analyzed, multiplied by 100.
Time frame: Up to 26 and 52 weeks
Change From Baseline in Fasting Blood Glucose (FBG) at 26 Weeks and 52 Weeks
LS means of change from baseline were calculated using MMRM with the change in FBG as the dependent variable and treatment, baseline value, country, OAM, visit, and treatment-by-visit interaction as fixed effects, and participant was the random effect.
Time frame: Baseline, 26 Weeks, 52 Weeks
Change From Baseline in 7-point Self-monitored Blood Glucose (SMBG) Profiles at 26 Weeks and 52 Weeks
Participants were required to perform 7-point SMBG profiles on 2 separate, nonconsecutive days during the 2 weeks before randomization and Weeks 8, 14, 20, 26, 39, and 52 (or the Early Discontinuation Visit). SMBG measurements were taken using a plasma-equivalent blood glucose (BG) meter at 7 time points: morning pre-meal, morning 2 hours post-meal, mid-day pre-meal, mid-day 2 hours post-meal, evening pre-meal, evening 2 hours post-meal, and at bedtime. Mean and Week 26 and Week 52 was assessed in all treatment groups. LS means of change from baseline were calculated using MMRM with the change in 7-point SMBG as the dependent variable and treatment, baseline value, country, OAM, visit, and treatment-by-visit interaction as fixed effects, and participant was the random effect.
Time frame: Baseline, 26 Weeks, 52 Weeks
Change From Baseline in Homeostasis Model Assessment 2 Steady-state Beta (β)- Cell Function (HOMA2-%B) at 26 Weeks and 52 Weeks
The updated Homeostasis Model Assessment (HOMA2) was used to quantify steady state beta-cell function (%B). HOMA2-%B is a computer model that uses fasting plasma insulin and glucose concentrations to estimate %B as a percentage of a normal reference population. LS means were calculated using a homeostasis model assessment with change from baseline in HOMA-%B as a covariate and country, baseline measurement, OAM, and treatment as fixed effects.
Time frame: Baseline, 26 weeks, 52 weeks
Change From Baseline in Homeostasis Model Assessment 2 Insulin Sensitivity - Cell Function (HOMA2-%S) at 26 Weeks and 52 Weeks
The HOMA2 was used to estimate the steady-state insulin sensitivity (%S). HOMA2-S is a computer model that uses fasting plasma insulin and glucose concentrations to estimate insulin sensitivity (%S) as a percentage of the normal reference population. LS means were calculated using an homeostasis model assessment with change from baseline in HOMA-%S as a covariate and country, baseline measurement, OAM, and treatment as fixed effects.
Time frame: Baseline, 26 Weeks, 52 Weeks
Rate of Hypoglycemic Events
Hypoglycemic events (HE) were classified as documented symptomatic hypoglycemia, asymptomatic hypoglycemia, severe hypoglycemia, and probable symptomatic hypoglycemia. The 1-year adjusted rate of HEs was summarized cumulatively at 26 weeks and 52 weeks. A summary of serious and other non-serious adverse events regardless of causality is located in the Reported Adverse Events module.
Time frame: Baseline through 26 weeks and 52 weeks
Number of Self-reported Hypoglycemic Events
Hypoglycemic events (HE) were classified as severe (defined as episodes requiring the assistance of another person to actively administer resuscitative actions), documented symptomatic (defined as any time a participant felt that he/she was experiencing symptoms and/or signs associated with hypoglycemia, and had a plasma glucose level of less than or equal to 3.9 millimoles/liter \[mmol/L\]), asymptomatic (defined as events not accompanied by typical symptoms of hypoglycemia but with a measured plasma glucose of less than or equal to 3.9 mmol/L), nocturnal (defined as any hypoglycemic event that occurred between bedtime and waking), or probable symptomatic (defined as events during which symptoms of hypoglycemia were not accompanied by a plasma glucose determination). The number of self-reported hypoglycemic events was summarized cumulatively at 52 weeks. A summary of serious and other non-serious adverse events regardless of causality is located in the Reported Adverse Events module.
Time frame: Baseline through 26 Weeks and 52 Weeks
Change From Baseline to 26 Weeks and 52 Weeks on Blood Pressure (BP)
Seated systolic blood pressure (SBP) and seated diastolic blood pressure (DBP) were measured. LS means of change from baseline were calculated using a MMRM with treatment, country, visit, and treatment-by-visit interaction as fixed effects and baseline as a covariate.
Time frame: Baseline, 26 Weeks, 52 Weeks
Change From Baseline at 26 Weeks and 52 Weeks on Pulse Rate
Seated pulse rate was measured. LS means of change from baseline were calculated using a MMRM with treatment, country, visit, and treatment-by-visit interaction as fixed effects and baseline as a covariate.
Time frame: Baseline, 26 Weeks, 52 Weeks
Change From Baseline in Electrocardiogram Parameters, Fridericia Corrected QT (QTcF) Interval and PR Interval
The QT interval is a measure of the time between the start of the Q wave and the end of the T wave and was calculated from electrocardiogram (ECG) data using Fridericia's formula: QTc = QT/RR\^0.33. Corrected QT (QTc) is the QT interval corrected for heart rate and RR, which is the interval between two R waves. PR is the interval between the P wave and the QRS complex.
Time frame: Baseline, 26 Weeks, 52 Weeks
Change From Baseline in Electrocardiogram Parameters, Heart Rate (HR)
Time frame: Baseline, 26 Weeks, 52 Weeks
Change From Baseline in Pancreatic Enzymes
Amylase (total and pancreas-derived) and lipase concentrations were measured
Time frame: Baseline, 26 Weeks, 52 Weeks
Change From Baseline in Serum Calcitonin
Time frame: Baseline, 26 Weeks, 52 Weeks
Number of Participants With Adjudicated Cardiovascular (CV) Events
Deaths and nonfatal cardiovascular adverse events were adjudicated by a committee of physicians with cardiology expertise external to the Sponsor. The nonfatal cardiovascular events subjected to adjudication included myocardial infarction, hospitalization for unstable angina, hospitalization for heart failure, coronary interventions (such as coronary artery bypass graft or percutaneous coronary intervention), and cerebrovascular events including cerebrovascular accident (stroke) and transient ischemic attack. A summary of serious and other non-serious adverse events regardless of causality is located in the Reported Adverse Events module.
Time frame: Baseline through 52 weeks
Number of Participants With Adjudicated Pancreatitis
The number of participants with pancreatitis confirmed by adjudication is summarized. Events of pancreatitis (including suspected pancreatitis and severe or serious abdominal pain) were adjudicated by a committee of expert physicians external to the Sponsor. A summary of serious and other non-serious adverse events regardless of causality is located in the Reported Adverse Events module.
Time frame: Baseline through 52 Weeks
Change From Baseline in Body Weight
Time frame: Baseline, 26 Weeks, 52 Weeks
Change in Body Mass Index
Body mass index is an estimate of body fat based on body weight divided by height squared.
Time frame: Baseline, 26 Weeks, 52 Weeks
Percentages of Participants Developing Treatment-Emergent Dulaglutide Anti-drug Antibody (ADA)
Number of participants with treatment emergent (TE) dulaglutide anti-drug antibodies from postbaseline to follow up were summarized. A participant was considered to have TE dulaglutide ADA if the participant had at least one titer that was treatment-emergent relative to baseline, defined as a 4-fold or greater increase in titer from baseline measurement.
Time frame: Baseline through 52 Weeks
EQ-5D Health State Score Responses
The EQ-5D questionnaire is a widely used, generic questionnaire that assesses health-related quality of life. It consists of 2 parts. The first part assesses 5 dimensions associated with quality of life (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression). Each dimension has 3 possible levels of response: no problem, some problem, and extreme problem. Additional categories of response include ambiguous and missing. The number of participants per each of the 3 response categories is summarized for each of the 5 dimensions.
Time frame: Baseline, 26 Weeks, 52 Weeks
Change From Baseline in EQ-5D Visual Analog Scale Score
The EQ-5D is a generic, multidimensional, health-related, quality-of-life instrument. Overall health state score was self-reported using a visual analogue scale (VAS) marked on a scale of 0 to 100 with 0 representing worst imaginable health state and 100 representing best imaginable health state. LS means of change from baseline were calculated using ANCOVA and adjusted by treatment, country, and baseline.
Time frame: Baseline, 26 weeks, 52 weeks
| Milestone | 1.5 mg Dulaglutide | 0.75 mg Dulaglutide | Insulin Glargine |
|---|---|---|---|
| Started | 258 | 257 | 259 |
| Received at least one dose of study drug | 258 | 257 | 259 |
| Modified intent-to-treat population | 253 | 252 | 250 |
| Completed | 226 | 219 | 227 |
| Not completed | 32 | 38 | 32 |
| Withdrew: Adverse event | 6 | 11 | 2 |
| Withdrew: Lost to follow-up | 9 | 6 | 8 |
| Withdrew: Protocol violation | 1 | 2 | 1 |
| Withdrew: Withdrawal by subject | 15 | 17 | 17 |
| Withdrew: Physician decision | 0 | 1 | 3 |
| Withdrew: Death | 1 | 0 | 0 |
| Withdrew: Sponsor decision | 0 | 1 | 1 |
HbA1c is a form of hemoglobin that is measured primarily to identify the average plasma glucose concentration over prolonged periods of time. Least square (LS) means of change from baseline in HbA1c were calculated using a mixed-effects model for repeated measures (MMRM) with the change in HbA1c as the dependent variable and treatment, baseline HbA1c, country, oral antihyperglycemic medication (OAM) , visit, and treatment-by-visit interaction as fixed effects, and participant was the random effect.
| percentage of HbA1c | 1.5 mg Dulaglutide | 0.75 mg Dulaglutide | Insulin Glargine |
|---|---|---|---|
| Change From Baseline in Glycosylated Hemoglobin (HbA1c) at 26 Weeks | -1.73 ± 0.067 | -1.33 ± 0.067 | -1.16 ± 0.067 |
HbA1c is a form of hemoglobin that is measured primarily to identify the average plasma glucose concentration over prolonged periods of time. LS means of change from baseline in HbA1c were calculated using a MMRM with the change in HbA1c as the dependent variable and treatment, baseline HbA1c, country, OAM, visit, and treatment-by-visit interaction as fixed effects, and participant was as the random effect.
| percentage of HbA1c | 1.5 mg Dulaglutide | 0.75 mg Dulaglutide | Insulin Glargine |
|---|---|---|---|
| Change From Baseline in HbA1c at 52 Weeks | -1.47 ± 0.076 | -1.03 ± 0.076 | -0.89 ± 0.075 |
The percentage of participants was calculated by dividing the number of participants reaching target HbA1c by the total number of participants analyzed, multiplied by 100.
| percentage of participants | 1.5 mg Dulaglutide | 0.75 mg Dulaglutide | Insulin Glargine |
|---|---|---|---|
| HbA1c <7%, Week 26 | 64.8 | 52.8 | 40.0 |
| HbA1c ≤6.5%, Week 26 | 51.4 | 38.9 | 21.6 |
| HbA1c <7%, Week 52 | 51.8 | 45.6 | 32.0 |
| HbA1c ≤6.5%, Week 52 | 37.2 | 31.3 | 17.2 |
LS means of change from baseline were calculated using MMRM with the change in FBG as the dependent variable and treatment, baseline value, country, OAM, visit, and treatment-by-visit interaction as fixed effects, and participant was the random effect.
| millimoles per liter (mmol/L) | 1.5 mg Dulaglutide | 0.75 mg Dulaglutide | Insulin Glargine |
|---|---|---|---|
| Change from baseline in FBG, 26 Weeks | -2.35 ± 0.162 | -1.71 ± 0.161 | -2.59 ± 0.161 |
| Change from baseline in FBG, 52 Weeks | -2.23 ± 0.166 | -1.53 ± 0.165 | -2.35 ± 0.164 |
Participants were required to perform 7-point SMBG profiles on 2 separate, nonconsecutive days during the 2 weeks before randomization and Weeks 8, 14, 20, 26, 39, and 52 (or the Early Discontinuation Visit). SMBG measurements were taken using a plasma-equivalent blood glucose (BG) meter at 7 time points: morning pre-meal, morning 2 hours post-meal, mid-day pre-meal, mid-day 2 hours post-meal, evening pre-meal, evening 2 hours post-meal, and at bedtime. Mean and Week 26 and Week 52 was assessed in all treatment groups. LS means of change from baseline were calculated using MMRM with the change in 7-point SMBG as the dependent variable and treatment, baseline value, country, OAM, visit, and treatment-by-visit interaction as fixed effects, and participant was the random effect.
| mmol/L | 1.5 mg Dulaglutide | 0.75 mg Dulaglutide | Insulin Glargine |
|---|---|---|---|
| Morning pre-meal, Week 26 | -2.18 ± 0.104 | -1.89 ± 0.103 | -2.83 ± 0.103 |
| Morning 2 hours post-meal, Week 26 | -3.81 ± 0.190 | -3.43 ± 0.188 | -3.32 ± 0.188 |
| Mid-day pre-meal, Week 26 | -2.45 ± 0.159 | -2.07 ± 0.157 | -2.10 ± 0.157 |
| Mid-day 2 hours post-meal, Week 26 | -3.16 ± 0.182 | -2.71 ± 0.179 | -2.11 ± 0.179 |
| Evening pre-meal, Week 26 | -2.25 ± 0.150 | -1.74 ± 0.147 | -1.62 ± 0.148 |
| Evening 2 hours post-meal, Week 26 | -3.00 ± 0.180 | -2.58 ± 0.178 | -2.11 ± 0.178 |
| Bed time, Week 26 | -2.95 ± 0.170 | -2.51 ± 0.167 | -2.16 ± 0.167 |
| Morning pre-meal, Week 52 | -2.06 ± 0.108 | -1.76 ± 0.108 | -2.83 ± 0.107 |
| Morning 2 hours post-meal, Week 52 | -3.58 ± 0.201 | -3.25 ± 0.200 | -3.05 ± 0.197 |
| Mid-day pre-meal, Week 52 | -2.37 ± 0.162 | -1.89 ± 0.162 | -1.94 ± 0.160 |
| Mid-day 2 hours post-meal, Week 52 | -2.75 ± 0.187 | -2.61 ± 0.186 | -2.12 ± 0.184 |
| Evening pre-meal, Week 52 | -2.15 ± 0.159 | -1.61 ± 0.158 | -1.51 ± 0.156 |
| Evening 2 hours post-meal, Week 52 | -2.93 ± 0.183 | -2.54 ± 0.182 | -2.10 ± 0.180 |
| Bed time, Week 52 | -2.90 ± 0.172 | -2.50 ± 0.171 | -1.91 ± 0.168 |
The updated Homeostasis Model Assessment (HOMA2) was used to quantify steady state beta-cell function (%B). HOMA2-%B is a computer model that uses fasting plasma insulin and glucose concentrations to estimate %B as a percentage of a normal reference population. LS means were calculated using a homeostasis model assessment with change from baseline in HOMA-%B as a covariate and country, baseline measurement, OAM, and treatment as fixed effects.
| percentage of HOMA2-%B | 1.5 mg Dulaglutide | 0.75 mg Dulaglutide |
|---|---|---|
| Insulin-Based HOMA2-%B, 26 Weeks | 34.41 ± 3.831 | 31.17 ± 3.761 |
| Insulin-Based HOMA2-%B, 52 Weeks | 45.12 ± 4.147 | 36.64 ± 4.061 |
The HOMA2 was used to estimate the steady-state insulin sensitivity (%S). HOMA2-S is a computer model that uses fasting plasma insulin and glucose concentrations to estimate insulin sensitivity (%S) as a percentage of the normal reference population. LS means were calculated using an homeostasis model assessment with change from baseline in HOMA-%S as a covariate and country, baseline measurement, OAM, and treatment as fixed effects.
| percentage of HOMA2-%S | 1.5 mg Dulaglutide | 0.75 mg Dulaglutide |
|---|---|---|
| Insulin-Based HOMA2-%S, Week 26 | -6.86 ± 3.649 | -10.03 ± 3.591 |
| Insulin-Based HOMA2-%S, Week 52 | -10.19 ± 3.677 | -12.32 ± 3.609 |
Hypoglycemic events (HE) were classified as documented symptomatic hypoglycemia, asymptomatic hypoglycemia, severe hypoglycemia, and probable symptomatic hypoglycemia. The 1-year adjusted rate of HEs was summarized cumulatively at 26 weeks and 52 weeks. A summary of serious and other non-serious adverse events regardless of causality is located in the Reported Adverse Events module.
| events per participant per year | 1.5 mg Dulaglutide | 0.75 mg Dulaglutide | Insulin Glargine |
|---|---|---|---|
| 1-year Rate of HE, Week 26 | 1.27 ± 4.485 | 0.98 ± 4.202 | 2.13 ± 6.724 |
| Severe HE Week 26 | NA ± NA | NA ± NA | NA ± NA |
| Nocturnal HE Week 26 | 0.19 ± 0.904 | 0.13 ± 0.762 | 0.38 ± 1.444 |
| 1-year Rate of HE, Week 52 | 0.89 ± 3.777 | 0.80 ± 3.914 | 1.92 ± 6.983 |
| Severe HE Week 52 | NA ± NA | NA ± NA | NA ± NA |
| Nocturnal HE Week 52 | 0.11 ± 0.488 | 0.10 ± 0.551 | 0.31 ± 1.261 |
Hypoglycemic events (HE) were classified as severe (defined as episodes requiring the assistance of another person to actively administer resuscitative actions), documented symptomatic (defined as any time a participant felt that he/she was experiencing symptoms and/or signs associated with hypoglycemia, and had a plasma glucose level of less than or equal to 3.9 millimoles/liter \[mmol/L\]), asymptomatic (defined as events not accompanied by typical symptoms of hypoglycemia but with a measured plasma glucose of less than or equal to 3.9 mmol/L), nocturnal (defined as any hypoglycemic event that occurred between bedtime and waking), or probable symptomatic (defined as events during which symptoms of hypoglycemia were not accompanied by a plasma glucose determination). The number of self-reported hypoglycemic events was summarized cumulatively at 52 weeks. A summary of serious and other non-serious adverse events regardless of causality is located in the Reported Adverse Events module.
| percentage of participants | 1.5 mg Dulaglutide | 0.75 mg Dulaglutide | Insulin Glargine |
|---|---|---|---|
| Total HE Week 26 | 19.4 | 16.7 | 29.6 |
| Severe HE Week 26 | 0.0 | 0.0 | 0.0 |
| Nocturnal HE Week 26 | 6.2 | 3.9 | 11.1 |
| Documented Symptomatic Week 26 | 11.2 | 7.8 | 17.0 |
| Asymptomatic HE Week 26 | 10.1 | 8.2 | 14.2 |
| Probable HE Week 26 | 4.3 | 5.1 | 7.5 |
| Total HE Week 52 | 22.5 | 19.8 | 34.8 |
| Severe HE Week 52 | 0.0 | 0.0 | 0.0 |
| Nocturnal HE Week 52 | 7.0 | 4.3 | 13.8 |
| Documented Symptomatic HE Week 52 | 12.4 | 9.7 | 20.6 |
| Asymptomatic HE Week 52 | 12.0 | 10.1 | 19.4 |
| Probable HE Week 52 | 4.7 | 5.4 | 8.3 |
Seated systolic blood pressure (SBP) and seated diastolic blood pressure (DBP) were measured. LS means of change from baseline were calculated using a MMRM with treatment, country, visit, and treatment-by-visit interaction as fixed effects and baseline as a covariate.
| millimeters of mercury (mmHg)] | 1.5 mg Dulaglutide | 0.75 mg Dulaglutide | Insulin Glargine |
|---|---|---|---|
| SBP 26 Weeks | -5.53 ± 12.037 | -2.77 ± 11.920 | -2.22 ± 12.743 |
| DBP 26 Weeks | -1.58 ± 7.842 | -0.92 ± 7.898 | -1.61 ± 8.417 |
| SBP 52 Weeks | -2.18 ± 11.134 | -0.61 ± 12.081 | -0.25 ± 11.717 |
| DBP 52 Weeks | -0.19 ± 7.542 | 0.44 ± 7.582 | -1.13 ± 8.810 |
Seated pulse rate was measured. LS means of change from baseline were calculated using a MMRM with treatment, country, visit, and treatment-by-visit interaction as fixed effects and baseline as a covariate.
| beats per minute (bpm) | 1.5 mg Dulaglutide | 0.75 mg Dulaglutide | Insulin Glargine |
|---|---|---|---|
| Change From Baseline on Pulse rate at Week 26 | 4.63 ± 8.681 | 0.65 ± 8.631 | -0.86 ± 9.546 |
| Change From Baseline on Pulse rate at Week 52 | 4.18 ± 8.336 | 3.18 ± 8.917 | 0.07 ± 8.205 |
The QT interval is a measure of the time between the start of the Q wave and the end of the T wave and was calculated from electrocardiogram (ECG) data using Fridericia's formula: QTc = QT/RR\^0.33. Corrected QT (QTc) is the QT interval corrected for heart rate and RR, which is the interval between two R waves. PR is the interval between the P wave and the QRS complex.
| millisecond (msec) | 1.5 mg Dulaglutide | 0.75 mg Dulaglutide | Insulin Glargine |
|---|---|---|---|
| QTcF Interval 26 Weeks | -1.65 ± 13.157 | 0.76 ± 11.643 | 2.56 ± 11.911 |
| PR Interval 26 Weeks | 3.09 ± 1.700 | 2.88 ± 10.801 | -0.86 ± 10.272 |
| QTcF Interval 52 Weeks | 0.55 ± 11.209 | 1.19 ± 12.165 | 4.03 ± 11.446 |
| PR Interval 52 Weeks | 3.60 ± 12.425 | 3.55 ± 11.526 | 0.63 ± 11.861 |
| beats per minute (bpm) | 1.5 mg Dulaglutide | 0.75 mg Dulaglutide | Insulin Glargine |
|---|---|---|---|
| Week 26 | 6.13 ± 8.924 | 3.77 ± 9.002 | -0.46 ± 9.329 |
| Week 52 | 5.04 ± 8.223 | 3.40 ± 7.986 | 0.43 ± 8.060 |
Amylase (total and pancreas-derived) and lipase concentrations were measured
| Units/Liter (U/L) | 1.5 mg Dulaglutide | 0.75 mg Dulaglutide | Insulin Glargine |
|---|---|---|---|
| Amylase, Total 26 Weeks | 7.50 ± 18.755 | 7.54 ± 22.388 | -0.37 ± 18.196 |
| Amylase, pancreas derived 26 Weeks | 5.83 ± 14.607 | 5.14 ± 19.360 | -0.21 ± 11.287 |
| Lipase 26 Weeks | 11.00 ± 34.134 | 10.67 ± 39.989 | -2.74 ± 21.818 |
| Amylase, Total 52 Weeks | 7.82 ± 16.250 | 6.42 ± 20.675 | 0.64 ± 18.696 |
| Amylase, pancreas derived 52 Weeks | 5.48 ± 12.449 | 4.05 ± 15.490 | -0.49 ± 12.576 |
| Lipase 52 Weeks | 10.76 ± 27.360 | 9.64 ± 33.715 | -3.66 ± 20.484 |
| picomole/liter | 1.5 mg Dulaglutide | 0.75 mg Dulaglutide | Insulin Glargine |
|---|---|---|---|
| Week 26 | 0.01 ± 0.240 | -0.07 ± 0.289 | 0.02 ± 0.256 |
| Week 52 | -0.03 ± 0.279 | -0.08 ± 0.325 | -0.05 ± 0.306 |
Deaths and nonfatal cardiovascular adverse events were adjudicated by a committee of physicians with cardiology expertise external to the Sponsor. The nonfatal cardiovascular events subjected to adjudication included myocardial infarction, hospitalization for unstable angina, hospitalization for heart failure, coronary interventions (such as coronary artery bypass graft or percutaneous coronary intervention), and cerebrovascular events including cerebrovascular accident (stroke) and transient ischemic attack. A summary of serious and other non-serious adverse events regardless of causality is located in the Reported Adverse Events module.
| participants with adjudicated CV events | 1.5 mg Dulaglutide | 0.75 mg Dulaglutide | Insulin Glargine |
|---|---|---|---|
| Number of Participants With Adjudicated Cardiovascular (CV) Events | 6 | 2 | 2 |
The number of participants with pancreatitis confirmed by adjudication is summarized. Events of pancreatitis (including suspected pancreatitis and severe or serious abdominal pain) were adjudicated by a committee of expert physicians external to the Sponsor. A summary of serious and other non-serious adverse events regardless of causality is located in the Reported Adverse Events module.
| participants | 1.5 mg Dulaglutide | 0.75 mg Dulaglutide | Insulin Glargine |
|---|---|---|---|
| Number of Participants With Adjudicated Pancreatitis | 0 | 0 | 0 |
| kilogram (kg) | 1.5 mg Dulaglutide | 0.75 mg Dulaglutide | Insulin Glargine |
|---|---|---|---|
| Week 26 | -1.47 ± 0.197 | -0.88 ± 0.197 | 0.97 ± 0.198 |
| Week 52 | -1.08 ± 0.201 | -0.76 ± 0.202 | 1.35 ± 0.201 |
Body mass index is an estimate of body fat based on body weight divided by height squared.
| kilogram/square meter (kg/m2) | 1.5 mg Dulaglutide | 0.75 mg Dulaglutide | Insulin Glargine |
|---|---|---|---|
| Week 26 | -0.53 ± 0.071 | -0.32 ± 0.071 | 0.37 ± 0.071 |
| Week 52 | -0.40 ± 0.072 | -0.27 ± 0.072 | 0.52 ± 0.072 |
Number of participants with treatment emergent (TE) dulaglutide anti-drug antibodies from postbaseline to follow up were summarized. A participant was considered to have TE dulaglutide ADA if the participant had at least one titer that was treatment-emergent relative to baseline, defined as a 4-fold or greater increase in titer from baseline measurement.
| Percentage of participants | 1.5 mg Dulaglutide | 0.75 mg Dulaglutide | Insulin Glargine |
|---|---|---|---|
| Participants with >=1 TE Dula ADA | 3.9 | 4.3 | 1.6 |
| Participants with TE Dula ADA and Neutralizing | 0.8 | 1.6 | 0.0 |
The EQ-5D questionnaire is a widely used, generic questionnaire that assesses health-related quality of life. It consists of 2 parts. The first part assesses 5 dimensions associated with quality of life (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression). Each dimension has 3 possible levels of response: no problem, some problem, and extreme problem. Additional categories of response include ambiguous and missing. The number of participants per each of the 3 response categories is summarized for each of the 5 dimensions.
| participants | 1.5 mg Dulaglutide | 0.75 mg Dulaglutide | Insulin Glargine |
|---|---|---|---|
| Mobility - no problem Week 26 | 219 | 215 | 210 |
| Mobility - some problem Week 26 | 7 | 16 | 20 |
| Mobility - extreme problem Week 26 | 0 | 0 | 0 |
| Mobility - missing Week 26 | 4 | 1 | 4 |
| Self-care - no problem Week 26 | 223 | 227 | 224 |
| Self-care - some problem Week 26 | 0 | 0 | 0 |
| Self-care - extreme problem Week 26 | 0 | 0 | 0 |
| Self-care - missing Week 26 | 4 | 1 | 4 |
| Usual activities - no problems Week 26 | 219 | 220 | 218 |
| Usual activities - some problems Week 26 | 7 | 11 | 11 |
| Usual activities - extreme problems Week 26 | 0 | 0 | 0 |
| Usual activities - missing Week 26 | 4 | 1 | 4 |
| Pain/Discomfort - no problems Week 26 | 193 | 201 | 188 |
| Pain/Discomfort - some problems Week 26 | 32 | 30 | 37 |
| Pain/Discomfort - ambiguous | 0 | 0 | 0 |
| Pain/Discomfort - missing Week 26 | 4 | 1 | 4 |
| Anxiety/Depression - no problems Week 26 | 208 | 204 | 203 |
| Anxiety/Depression - some problems Week 26 | 19 | 27 | 26 |
| Anxiety/Depression - extreme problems Week 26 | 0 | 0 | 1 |
| Anxiety/Depression - missing Week 26 | 4 | 1 | 4 |
| Mobility - no problems Week 52 | 218 | 207 | 214 |
| Mobility - some problems Week 52 | 8 | 14 | 16 |
| Mobility - extreme problems Week 52 | 0 | 1 | 0 |
| Mobility - missing Week 52 | 0 | 0 | 1 |
| Self-care - no problems Week 52 | 224 | 215 | 223 |
| Self-care - some problems Week 52 | 2 | 7 | 7 |
| Self-care - extreme problems Week 52 | 0 | 0 | 0 |
| Self-care - missing Week 52 | 0 | 0 | 1 |
| Usual Activities - no problems Week 52 | 219 | 211 | 219 |
| Usual Activities - some problems Week 52 | 6 | 10 | 11 |
| Usual Activities - extreme problems Week 52 | 1 | 1 | 0 |
| Usual Activities - missing Week 52 | 0 | 0 | 1 |
| Pain/Discomfort - no problems Week 52 | 191 | 188 | 185 |
| Pain/Discomfort - some problems Week 52 | 34 | 33 | 43 |
| Pain/Discomfort - extreme problems Week 52 | 1 | 1 | 1 |
| Pain/Discomfort - missing Week 52 | 0 | 0 | 1 |
| Anxiety/Depression - no problems Week 52 | 205 | 207 | 201 |
| Anxiety/Depression - some problems Week 52 | 21 | 15 | 29 |
| Anxiety/Depression - extreme problems Week 52 | 0 | 0 | 0 |
| Anxiety/Depression - missing Week 52 | 0 | 0 | 1 |
The EQ-5D is a generic, multidimensional, health-related, quality-of-life instrument. Overall health state score was self-reported using a visual analogue scale (VAS) marked on a scale of 0 to 100 with 0 representing worst imaginable health state and 100 representing best imaginable health state. LS means of change from baseline were calculated using ANCOVA and adjusted by treatment, country, and baseline.
| units on a scale | 1.5 mg Dulaglutide | 0.75 mg Dulaglutide | Insulin Glargine |
|---|---|---|---|
| Week 26 | 1.08 ± 12.644 | 1.67 ± 13.456 | 1.41 ± 10.885 |
| Week 52 | 2.65 ± 12.029 | 2.34 ± 14.003 | 2.55 ± 12.257 |
Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| 1.5 mg Dulaglutide | — | 24/258 (9.3%) | 184/258 (71.3%) |
| 0.75 mg Dulaglutide | — | 15/257 (5.8%) | 188/257 (73.2%) |
| Insulin Glargine | — | 9/253 (3.6%) | 157/253 (62.1%) |
| Event | 1.5 mg Dulaglutide | 0.75 mg Dulaglutide | Insulin Glargine |
|---|---|---|---|
| Benign ovarian tumourNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/119 | 1/113 | 0/112 |
| Coronary artery diseaseCardiac disorders | 2/258 | 0/257 | 0/253 |
| PancreatitisGastrointestinal disorders | 2/258 | 0/257 | 0/253 |
| PeriarthritisMusculoskeletal and connective tissue disorders | 2/258 | 0/257 | 0/253 |
| Transient ischaemic attackNervous system disorders | 2/258 | 1/257 | 0/253 |
| Angina unstableCardiac disorders | 0/258 | 0/257 | 1/253 |
| ExtrasystolesCardiac disorders | 0/258 | 0/257 | 1/253 |
| Sinus node dysfunctionCardiac disorders | 0/258 | 0/257 | 1/253 |
| Vision blurredEye disorders | 0/258 | 0/257 | 1/253 |
| BronchitisInfections and infestations | 1/258 | 0/257 | 1/253 |
| Event | 1.5 mg Dulaglutide | 0.75 mg Dulaglutide | Insulin Glargine |
|---|---|---|---|
| HyperlipidaemiaMetabolism and nutrition disorders | 46/258 | 50/257 | 47/253 |
| DiarrhoeaGastrointestinal disorders | 43/258 | 28/257 | 7/253 |
| HypertensionVascular disorders | 20/258 | 28/257 | 19/253 |
| NauseaGastrointestinal disorders | 27/258 | 14/257 | 2/253 |
| Lipase increasedInvestigations | 27/258 | 18/257 | 2/253 |
| NasopharyngitisInfections and infestations | 18/258 | 17/257 | 22/253 |
| Decreased appetiteMetabolism and nutrition disorders | 19/258 | 14/257 | 0/253 |
| Abdominal distensionGastrointestinal disorders | 18/258 | 13/257 | 0/253 |
| VomitingGastrointestinal disorders | 16/258 | 6/257 | 2/253 |
| Urinary tract infectionInfections and infestations | 13/258 | 14/257 | 11/253 |
Baseline characteristics are reported for the modified intent-to-treat (mITT) population, who are all randomized participants with a baseline glycosylated hemoglobin (HbA1c) measurement, at least 1 post-baseline HbA1c measurement, and received at least 1 dose of study drug.
| Age, Continuous(years) | 1.5 mg Dulaglutide | 0.75 mg Dulaglutide | Insulin Glargine | Total |
|---|---|---|---|---|
| Mean | 55.03 ± 9.572 | 54.54 ± 10.006 | 55.44 ± 9.197 | 55.00 ± 9.593 |
| Sex: Female, Male(Participants) | 1.5 mg Dulaglutide | 0.75 mg Dulaglutide | Insulin Glargine | Total |
|---|---|---|---|---|
| Female | 118 | 109 | 111 | 338 |
| Male | 135 | 143 | 139 | 417 |
| Race (NIH/OMB)(Participants) | 1.5 mg Dulaglutide | 0.75 mg Dulaglutide | Insulin Glargine | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 14 | 14 | 13 | 41 |
| Asian | 213 | 209 | 209 | 631 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 | 0 |
| White | 26 | 29 | 28 | 83 |
| More than one race | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
| Region of Enrollment(Participants) | 1.5 mg Dulaglutide | 0.75 mg Dulaglutide | Insulin Glargine | Total |
|---|---|---|---|---|
| China | 200 | 196 | 195 | 591 |
| Korea, Republic of | 13 | 13 | 14 | 40 |
| Mexico | 22 | 24 | 24 | 70 |
| Russian Federation | 18 | 19 | 17 | 54 |
Plan to share: Yes — Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.
Supporting information: Study protocol, Statistical analysis plan, Clinical study report
Time frame: Data are available 6 months after the primary publication and approval of the indication studied in the US and EU, whichever is later. Data will be indefinitely available for requesting.
Access criteria: A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.
Data sharing details ↗ · vivli.org
The record gives a start of Jul 2012, a primary completion of Aug 2014 and a completion of Dec 2014. It does not say whether these dates are actual or estimated.
Results were first posted in Jul 2015, 11 months after primary completion. A results delay was requested in Sep 2014.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Dulaglutide